The deal positions MilliporeSigma at the center of commercial manufacturing for three breakthrough gene therapies targeting sickle cell disease, ?-thalassemia, and cerebral adrenoleukodystrophy
The device is designed for early and accurate diagnosis of obstructive airway diseases such as COPD, and Asthma
Approval marks the second generic semaglutide clearance in Canada and strengthens OneSource’s position in complex injectable CDMO programs
The ISG assessment highlights Indegene’s deep domain expertise, proprietary technology stack, and expanding use of AI and GenAI to drive more integrated, data-led commercial execution across the life sciences value chain
Approval expands Lupin’s specialty portfolio in the US market for treatment of urea cycle disorders
Under the new policy, financial assistance has been increased to Rs 50 lakh per patient to improve treatment access
Approval for generic Ozempic® in Canada strengthens OneSource’s global CDMO footprint in complex peptide injectable manufacturing
Market authorization for generic GLP-1 therapy strengthens company’s diabetes portfolio in Canada
Wadhwa brings over two decades of experience driving growth, transformation, and customer-centric strategies in the medical devices and diagnostics sector
Both join the leading CRDMO’s executive committee to drive global people strategy and commercial expansion
Subscribe To Our Newsletter & Stay Updated
